Roche Holding AG
Novo Nordisk cuts 2025 guidance as drug copycats hit Wegovy sales, posts first-quarter profit beat
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk on Wednesday reported a better-than-expected rise in […]
Read More
Inside the deal: Roche and Zealand Pharma’s $5.3 billion obesity drug gambit
A view of the sign and logo of the Roche Holding AG headquarters on April 11, 2025 in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma’s “next generation” […]
Read More
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump’s pharma tariffs loom
Jgi/jamie Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Tariff threats — and efforts to get into President Donald Trump’s good graces — are fueling a new wave […]
Read More
Roche to invest $50 billion in the U.S. as pharma tariff threat lingers
A photo showing the logo of Swiss pharmaceutical giant Roche in Basel. SEBASTIEN BOZON | AFP | Getty Images Swiss pharmaceutical giant Roche on Tuesday said that it would invest $50 billion in the U.S. over the next five years, amid concerns about the impact of possible new White House tariffs on pharma goods from […]
Read More
Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients
Eli Lilly on Thursday said its daily obesity pill met the company’s goals in the first of several late-stage trials, helping Type 2 diabetes patients lower their blood sugar and body weight and showing safety on par with popular injections on the market. The trial results are among the pharmaceutical industry’s most closely watched studies […]
Read More
Here are the top 15 companies for career growth in Singapore, according to LinkedIn
DBS Bank tops LinkedIn’s 2025 Top Companies in Singapore list. Lim Weixiang – Zeitgeist Photos | E+ | Getty Images The technology, banking and consulting industries dominated LinkedIn’s 2025 Top Companies in Singapore list published this month, which ranks the best workplaces for career growth in the city-state. The networking giant tracked and assessed companies […]
Read More
Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Boxes of Novo Nordisk’s weight-loss drug Wegovy in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting as the White House moves ahead with plans […]
Read More
Eli Lilly will soon release key data on its weight loss pill. Here’s why it could be a game-changer
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Eli Lilly plans to […]
Read More
Roche abandons global diversity targets on concern over U.S. executive orders
Sheldon Cooper | Lightrocket | Getty Images Swiss drugmaker Roche has abandoned global targets for a more diverse workforce to avoid penalties from recent U.S. executive orders, the latest in a slew of companies to do so. Among measures taken, Roche said its Chief Diversity Offices in the U.S. and at its Basel headquarters “will […]
Read More
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma’s obesity drug candidate, as the two firms seek to compete in the burgeoning weight loss drug market. The deal will see the two companies co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as […]
Read More